Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/321"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:content |
"Pharmacokinetics:
Following oral administration, leflunomide is metabolized to an active metabolite A77 1726 (hereafter referred to as M1) which is responsible for essentially all of its activity in vivo. Plasma levels of leflunomide are occasionally seen, at very low levels. Studies of the pharmacokinetics of leflunomide have primarily examined the plasma concentrations of this active metabolite.
NOTE: A77 1726 is referred to as 'teriflunomide' in the DIKB based on its common name in various literature sources including Wikipedia (http://en.wikipedia.org/wiki/Teriflunomide)"
|
| dc:creator | |
| dc:date |
"09/24/2009 12:09:57"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ leflunomide_has_metabolite_teriflunomide, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1447 }